Eye On A.I.

In this week's episode, we speak to Jose-Marie Griffiths, a commissioner on the National Security Commission on Artificial Intelligence, about the commission's recommendations on how to strengthen the federal government's AI workforce. The recommendations focused on raising understanding of AI within the government and the need to streamline government hiring practices in order to attract and retain talent.

In April 2020, the National Security Commission on Artificial Intelligence issued its first-quarter recommendations to Congress, covering seven lines of effort, six of which are public and one of which is classified. In the first of a series of podcast episodes about those recommendations, we spoke with Andrew Moore, a professor at Carnegie Mellon University and NSCAI commissioner about the commission's recommendations on increased AI R&D funding.

COVID-19 continues to sweep through the human population, killing some and damaging the health of others. While this podcast is normally focused on machine-learning, this week I talk to Vittorio Sebastiano, an assistant professor of stem cell biology at Stanford University, about groundbreaking tech that could someday help restore scarred tissue to pre-COVID health. Vittorio talked about his hunt for machine-learning collaborators to understand the process further.

COVID-19 has swept across the world was startling speed, but with equally startling speed, the machine learning community has responded. This week I speak with Irina Rish, a professor at the University of Montreal and a Mila academic member, who is helping head a task force to understand the virus. She talked about where the efforts currently stand and where they expect to go in the weeks and months ahead. Let me know when it's live.

There has been a debate in the past few years between the symbolists and the connectionists about the future of artificial intelligence. The symbolists say that traditional, explainable, logic-based approaches still hold tremendous promise while the connectionists say that the power of deep learning, for all its current opacity and narrow application, holds the key to more general forms of machine intelligence. This week, I speak with David Cox, IBM Director of the MIT-IBM Watson AI Lab, which is blending the two traditions in what they call neuro-symbolic AI in hopes to move AI forward.

Justin Gottschlich, who founded the machine programming research group at Intel Labs, explains his group's efforts to automate software development. The ambition is to make it possible for anybody to create software simply by describing what they intend the software to do.

This week I talk to Casimir Wierzynski, a senior director in Intel's AI Products Group, Cas talked about his work in privacy, taking me on a tour of the latest strategies that promise to unlock the data necessary to liberate AI. He talked about hardening encryption against the code-cracking power of quantum computers and about his work in connectomics with salami slicers for the brain that are making it possible to map the neural networks of our minds.

Terry Sejnowski, author of the book Deep Learning Revolution, who together with Geoff Hinton created Boltzmann machines, a deep learning network that has remarkable similarities to learning in the brain, talks about whether machines dream and the algorithms of the brain, whether Marvin Minsky was the devil and how deep learning is shaping the future of education.

The podcast discusses the application of AI in tackling the climate crisis, the competition between the US and China in AI innovation, and the future of machine learning with unsupervised learning. Topics include the urgency of transitioning to zero carbon energy, China's AI advantages, shifting from supervised to unsupervised learning, and robots learning in diverse environments.

Daphne Koller, formerly at Stanford University and cofounder of the online education company, Coursera, talks this week about using machine-learning to develop new drugs. Her approach is to use machine learning to accuratley identify cellular or genetic targets for treatment. The field is just getting started but promises to speed the development of new and better therapies to treat disease.